Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.44 |
| ▸ | PLAT | P00750 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | PRKACA | P17612 | 2/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.40 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17803212 | 0.86 | DRD2 (0.48) | DRD2DRD4DRD3PLATCALCRL | |
| SCHEMBL3962522 | 0.86 | DRD2 (0.61) | DRD2DRD4DRD3CA12CA1 | |
| SCHEMBL3253448 | 0.86 | DRD2 (0.48) | DRD2DRD4DRD3PLATCALCRL | |
| SCHEMBL2102005 | 0.85 | DRD2 (0.64) | DRD2DRD4DRD3CA12CA1 | |
| Hydrochloric Acid SCHEMBL2273497 | 0.85 | DRD2 (0.64) | DRD2DRD4DRD3CA12CA1 | |
| Hydrochloric Acid SCHEMBL5551325 | 0.85 | DRD2 (0.64) | DRD2DRD4DRD3CA12CA1 | |
| SCHEMBL14417268 | 0.85 | CTSS (0.52) | DRD2DRD4DRD3MAPK14PLAT | |
| SCHEMBL3957118 | 0.83 | DRD2 (0.46) | DRD2DRD4DRD3MAPK14PLAT | |
| SCHEMBL13801351 | 0.81 | DRD2 (0.53) | DRD2DRD4DRD3CA12CA1 | |
| SCHEMBL14410225 | 0.80 | DRD2 (0.49) | DRD2DRD4DRD3CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101103020-B | Cgrp receptor antagonists | MERCK & CO INC | 2011-04-27 | — | — | CN | disclosed |
| EP-1856100-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1856100-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| US-7632832-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632832-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632832-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20080125413-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080125413-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080125413-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-29 | — | — | US | disclosed |
| CN-101103020-A | CGRP receptor antagonists | MERCK & CO INC (US) | 2008-01-09 | — | — | CN | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | disclosed |
| EP-0927192-B1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | DRD2 187/4885DRD4 139/4885DRD3 160/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | DRD2 198/4885DRD4 125/4885DRD3 168/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | DRD2 130/4885DRD4 86/4885DRD3 106/4885 |
| US-20080125413-A1 | Cgrp Receptor Antagonists | CALCRL, NPY1R, CCKBR | DRD2 600/4885DRD4 1215/4885DRD3 623/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | DRD2 198/4885DRD4 125/4885DRD3 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.